A 56-year-old male patient with lymphoma received anti-tumor treatments with treprizumab (intravenous infusion of 240 mg once every 21 days) combined with rituximab, gemcitabine, and oxaliplatin. On day 5 after the first treatment of treprizumab, the patient developed rash all over the body and a large area of erythema on the trunk and limbs, accompanied by pruritus and pain, and the exfoliation area of the whole body was more than 30%. Laboratory tests showed white blood cell count 12.4×10 9/L, neutrophil count 11.5×10 9/L, erythrocyte sedimentation rate 162 mm/1 h, C-reactive protein 74 mg/L, and procalcitonin 1.09 μg/L. The patient had received antineoplastic therapy with rituximab, gemcitabine, and oxaliplatin and no skin reaction occurred. Stevens-Johnson syndrome induced by treprizumab was considered. Protective isolation care and symptomatic treatments such as glucocorticoid, immunoglobulin, and anti-infection were given. After 23 days of treatments, the patient was improved, and the skin ulceration area decreased to 10%. After 31 days of treatments, regenerated skin appeared under most of the ulcerated skin, and laboratory tests showed erythrocyte sedimentation rate 46 mm/1 h, C-reactive protein 15 mg/L, and procalcitonin 0.04 μg/L.

A 56-year-old male patient with lymphoma received anti-tumor treatments with treprizumab (intravenous infusion of 240 mg once every 21 days) combined with rituximab, gemcitabine, and oxaliplatin. On day 5 after the first treatment of treprizumab, the patient developed rash all over the body and a large area of erythema on the trunk and limbs, accompanied by pruritus and pain, and the exfoliation area of the whole body was more than 30%. Laboratory tests showed white blood cell count 12.4×10 9/L, neutrophil count 11.5×10 9/L, erythrocyte sedimentation rate 162 mm/1 h, C-reactive protein 74 mg/L, and procalcitonin 1.09 μg/L. The patient had received antineoplastic therapy with rituximab, gemcitabine, and oxaliplatin and no skin reaction occurred. Stevens-Johnson syndrome induced by treprizumab was considered. Protective isolation care and symptomatic treatments such as glucocorticoid, immunoglobulin, and anti-infection were given. After 23 days of treatments, the patient was improved, and the skin ulceration area decreased to 10%. After 31 days of treatments, regenerated skin appeared under most of the ulcerated skin, and laboratory tests showed erythrocyte sedimentation rate 46 mm/1 h, C-reactive protein 15 mg/L, and procalcitonin 0.04 μg/L.

OBJECTIVE： To mine the signals of osimertinib adverse drug event （ADEs） and to provide reference for clinical drug safety. METHODS： By reporting odd ratio （ROR） and Bayesian confidence propagation neural network （BCPNN） algorithms， data mining and signal detection were carried out on osimertinib-related ADEs reports with case number ≥3 reported by American Adverse Event Reporting System （FAERS） from Nov. 2015 to Jun. 2018. RESULTS & CONCLUSIONS： A total of 2 044 osimertinib-related ADEs were found， among which the female （1 285 cases） was more than the male （615 cases）， mainly aged 45-64 years （228 cases）， 65-74 years （241 cases）， ≥75 years （248 cases）； most of reporters were physicians （887 cases）. A total of 63 and 57 osimertinib ADEs signals were mined by ROR and BCPNN methods， and the latter signals overlapped with the former. The obtained signals included skin toxicity （dermatitis acneiform， rash， dry skin， onychoclasis， nail disorder， paronychia）， gastrointestinal tract reaction （decreased appetite， diarrhea， stomatitis）， respiratory diseases （interstitial pneumonia， pneumonia）， hematological diseases （platelet count decreased， white blood cell count decreased， neutrophil count decreased）， vascular events （pulmonary embolism， deep vein thrombosis）， electrocardiogram QT prolonged （RORs were 2.04-56.70， ICs were 0.97-4.43）， all of which had been recorded in drug instructions； obtained signals also included new suspicious signals not indicated in the drug instructions， such as liver damage， cerebral infarction， hyponatremia， atrial fibrillation， renal impairment， dehydration， dysgeusia， and so on （RORs were 2.06-161.74， ICs were 1.00-4.58）. In clinical use of osimertinib， besides paying close attention to known safety problems such as nail toxicity of finger （toe） and rash， interstitial pneumonia， electrocardiogram QT prolonged， we should also be alert to the occurrence of potential ADEs such as liver damage to ensure drug safety.

Objective To construct lentiviral vectors containing peptide P1-GFP fusion genes.Umbilical cord derived mesenchymal stem cells were infected with lentivirus carrying peptide P1 and GFP fusion genes.To inject the targeted umbilical cord derived mesenchymal stem cells into mice and to detect GFP expression in the spleen.Methods Umbilical cord derived mesenchymal stem cells were cultured with adhered tissues of umbilical cord smaller than 1 mm3 . Lentiviral vector containing P1-GFP fusion genes with engineering technology was constructed and infected the umbilical cord derive mesenchymal stem cells.Targeted umbilical cord derived mesenchymal stem cells were intravenously injected in the mouse tail vein and after 18 hours GFP expression was detected with immunohistochamical staining of the spleen tissues.Results Harvested umbilical cord derived mesenchymal stem cells grew well in culture medium. Green fluorescence on umbilical cord derived mesenchymal stem cells were observed under fluorescence microscope at 18 hours after infected with lentivirus.Green fluorescence intensity of umbilical cord derived mesenchymal stem cells was increasing over time and reached a peak at 72 hours.Umbilical cord derived mesenchymal stem cells highly expressed CD105 (90.0%)/CD44 (98%) and CD73 (85.0%)/CD90 (98.5%) molecules.GFP expression was detected in the spleen after intravenous injection of targeted umbilical cord derived mesenchymal stem cells in the mice 18 hours later.GFP expressing cells intimately contacted with lymphocytes.Conclusions Targeted umbilical cord derived mesenchymal stem cells contain P1-GFP fusion genes are constructed.Targeted umbilical cord derived mesenchymal stem cells can be targeted to mouse spleen and intimately contact with lymphocytes after intravenous injection.Our results lay the groundwork for further studies.